sgn 2

SGN-2FF 是一种岩藻糖基化抑制剂，具有口服活性，能够抑制岩藻糖基转移酶的活性，具有抗肿瘤活性。

HSGN-218 is a gut-restrictive antibiotic.1It is active againstC. difficile(MIC = 0.007 μg/ml) and clinical isolates ofC. difficile(MICs = 0.003-0.03 μg/ml) and is not cytotoxic to Caco-2 cells when used at concentrations ranging from 4 to 64 μg/ml. HSGN-218 (50 mg/kg) increases survival and protects mice fromC. difficilerecurrence in mouse models ofC. difficileinfection. 1.Naclerio, G.A., Abutaleb, N.S., Li, D., et al.Ultrapotent inhibitor of Clostridioides difficile growth, which suppresses recurrence in vivoJ. Med. Chem.63(20)11934-11944(2020)

MMAFintermediate 2 用于制备MMAF,后者是一种抗体偶联药物中的细胞毒性成分,具体是微管蛋白聚合抑制剂.MMAF (Monomethylauristatin F) 在多种ADCs中具有应用,例如 Vorsetuzumab mafodotin 和 SGN-CD19A,用于靶向疾病细胞进行治疗.

Ladiratuzumab vedotin (SGN-LIV1A) 是针对LIV-1的抗体药物偶联物(ADC) (IC50: 5.6 nM)，由人源化IgG1单克隆抗体、MMAE和蛋白酶-可切割型连接子组成，能够驱动免疫原性细胞死亡(ICD)以引发免疫反应，可用于乳腺癌研究。